特朗普万万没想到，除了稀土，中国还有一个王炸可以打败美国

Core Viewpoint - The ongoing trade war has highlighted the United States' dependency on China for critical resources, particularly in the rare earth and pharmaceutical sectors [1][3][4]. Group 1: Rare Earth Industry - A rare earth processing center in South Carolina has successfully produced its first domestic rare earth magnet, which has been interpreted by the media as a sign of a manufacturing revival in the U.S. [1] - Despite this achievement, the U.S. remains heavily reliant on China for both rare earth materials and pharmaceutical raw materials [1]. Group 2: Pharmaceutical Supply Chain - The pharmaceutical supply chain is identified as a crucial leverage point for China in U.S.-China negotiations, with China holding a dominant position in the global pharmaceutical market [3]. - As of the latest data, China accounts for 45% of global drug ingredient registrations, significantly outpacing India's 19% [3]. - China is the sole supplier of approximately 700 key drug core chemical components, indicating its deep integration into the global healthcare system [3]. Group 3: U.S. Political Response - U.S. political figures have reacted strongly, with calls for collaboration with allies like India to establish alternative supply chains to reduce dependency on China [4]. - The U.S. has previously imposed high tariffs on medical equipment and patented drugs from China, which could increase healthcare costs for American citizens [4]. Group 4: Innovation in Chinese Pharmaceutical Industry - China's pharmaceutical industry has transitioned from follower innovation to original innovation, enhancing its influence in new drug development and clinical trials [6]. - Efforts to decouple from China's pharmaceutical supply chain are deemed increasingly unrealistic, as even India, the largest generic drug producer, relies on Chinese raw materials [6]. - The globalized nature of supply chains makes it nearly impossible for the U.S. to achieve supply chain security through protectionist measures [6].